Loading stock data…
MRVI
$3.73+0.05 (+1.36%)
Market ClosedLast close May 1
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maravai LifeSciences Holdings, Inc. in the Healthcare sector is trading at $3.73. The stock is currently near its 52-week high of $4.11, remaining 18.4% above its 200-day moving average. Technical signals show neutral RSI of 69 and bullish MACD crossover, explaining why MRVI maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 69) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.73
Potential Upside
5%
Whystock Fair Value$3.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.65%
Volume
Today's trading volume
863,776
Recent News
Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 close, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) had a moderately bullish consensus sentiment. The stock received coverage from 6 analysts, 3 of whom assigned Buy ratings and 3 gave Hold calls. With no Sell […]
How Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation Narrative
The latest analyst update on Maravai LifeSciences Holdings centers on a price target move from US$2 to US$3, set against an unchanged fair value estimate of US$4.33 per share. Bullish and bearish analysts both tie this shift to Q4 results and refreshed models, with one side seeing the new target as better aligned with recent execution and the other highlighting that upside still looks limited relative to perceived risks. As you read on, you will see how this evolving narrative could shape...
How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets
Maravai LifeSciences Holdings is back in focus after analysts reset their price target around US$3, aligning it more closely with a refreshed model fair value of US$4.33 per share. The shift follows Q4 results that modestly beat consensus, prompting bullish analysts to see expectations as better tuned to current execution. More cautious voices still view the risk and reward as fairly balanced. Read on to see how these differing views shape the evolving story and what to watch as the narrative...
Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Maravai LifeSciences Holdings, Inc.'s Q4 2025 earnings call
Maravai LifeSciences Q4 Earnings Call Highlights
Maravai LifeSciences (NASDAQ:MRVI) executives told investors the company exited fiscal 2025 with improving operating leverage following a restructuring and a renewed emphasis on customer engagement, setting up management’s expectation for a return to growth and profitability in 2026. Fourth-quarter